POPE is a multinational, multicentre, prospective, observational, non-interventional registry of patients with chronic obstructive pulmonary disease (COPD) in Central and Eastern Europe. The aim of the POPE study is to assess the distribution of patients with COPD in clinical practice within the CEE region according to disease severity, disease category, and phenotypes. The study was initiated as the pilot cooperation of COPD PLATFORM in the CEE region and 11 countries from Central and Eastern Europe have been involved in the project.

POPE Study – Phenotypes of COPD in Central and Eastern Europe

Primary aim

  • To assess the prevalence of COPD phenotypes according to predefined criteria in an unselected group of consecutively examined patients with COPD in CEE region

Secondary aims

  • To determine the proportion of patients within the GOLD 2011 strategy disease severity (stage 1,2,3,4) and risk classification category (A,B,C,D) in patients with COPD in CEE region
  • To evaluate the diagnostic approach to COPD in CEE countries
  • To assess the differences in treatment habits in CEE countries



Inclusion criteria

  • Age > 40 years
  • Clinical diagnosis of COPD with post-BD FEV1/FVC <  0.7
  • Smoking burden ≥ 10 pack-years in smokers (group A). Evidence of exposure to at least one other typical inhaled COPD risk factor: ETS, professional exposures, etc. (group B).
  • Stable disease for at least 4 weeks
  • Outpatient status
  • Informed Consent

Exlusion criteria

Exclusion criteria are defined to distinguish other primary conditions that might produce symptoms similar to those of a COPD.

  • Exacerbation of COPD and/or instable co-morbid condition
  • Patient during hospital stay for whatever reason (lung or co-morbidities)
  • Patient is not able and willing to participate


The POPE project is registered in ClinicalTrials.gov with the identifier NCT02119494.